Warning: The NCBI web site requires JavaScript to function. more...
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K.
Retrovirology. 2004 Sep 17;1:27.
Related citations
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B, Yu X, Luo K, Yu Y, Yu XF.
J Virol. 2004 Feb;78(4):2072-81.
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K.
J Virol. 2003 Nov;77(21):11398-407.
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K.
J Virol. 2007 Aug;81(15):8236-46. Epub 2007 May 23.
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D.
J Biol Chem. 2004 Feb 27;279(9):7792-8. Epub 2003 Dec 13.
HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J, Santa-Marta M.
Retrovirology. 2004 Sep 21;1:28.
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR.
Cell. 2003 Jul 11;114(1):21-31.
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K, de Noronha C, Yonemoto W, Greene WC.
Mol Cell. 2003 Sep;12(3):591-601.
Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.
Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K.
Virology. 2007 Dec 20;369(2):329-39. Epub 2007 Sep 6.
Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G.
Takeuchi H, Kao S, Miyagi E, Khan MA, Buckler-White A, Plishka R, Strebel K.
J Biol Chem. 2005 Jan 7;280(1):375-82. Epub 2004 Nov 3.
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK.
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7. Epub 2004 Mar 30.
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
Huthoff H, Malim MH.
J Virol. 2007 Apr;81(8):3807-15. Epub 2007 Jan 31.
Functional domains of APOBEC3G required for antiviral activity.
Li J, Potash MJ, Volsky DJ.
J Cell Biochem. 2004 Jun 1;92(3):560-72.
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
Ribeiro AC, Maia e Silva A, Santa-Marta M, Pombo A, Moniz-Pereira J, Goncalves J, Barahona I.
J Virol. 2005 Jan;79(2):823-33.
A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W.
Med Hypotheses. 2005;64(2):261-3.
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S.
J Virol. 2006 Sep;80(18):9259-69. Erratum in: J Virol. 2007 Aug;81(16):8843-5.
HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J.
J Biol Chem. 2005 Mar 11;280(10):8765-75. Epub 2004 Dec 20.
APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T.
Retrovirology. 2005 May 19;2:32.
Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F, Cen S, Niu M, Saadatmand J, Kleiman L.
J Virol. 2006 Dec;80(23):11710-22. Epub 2006 Sep 13.
HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M, Aires da Silva F, Fonseca AM, Rato S, Goncalves J.
Mol Immunol. 2007 Jan;44(4):583-90. Epub 2006 Mar 31.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on